GlassScriptPhysician profile
Pamela Ann Smith
NPI 1780771824
$2,533.88
in general payments reported to CMS, 2019-2025
33 companies · $41.82 in 2025
The $41.82 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $54.08 · 2021: $859 · 2022: $260 · 2023: $369 · 2024: $783 · 2025: $41.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $992 · Education: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $991.66 |
| Education | $202.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $756.15 | 2021 | |
| Astellas Pharma US INC | $274.19 | 2023-2024 | Xospata, Xtandi, Padcev |
| Iovance Biotherapeutics, INC. | $196.28 | 2024 | Amtagvi |
| Novartis Pharmaceuticals Corporation | $178.85 | 2019-2024 | |
| Pfizer INC. | $170.13 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $100.64 | 2023-2025 | Lynparza, Imfinzi |
| Aveo Pharmaceuticals, INC. | $81.99 | 2022 | |
| Daiichi Sankyo INC. | $75.05 | 2022-2024 | Injectafer, Enhertu |
| Tesaro, INC. | $66.25 | 2019 | |
| Amgen INC. | $60.67 | 2020-2021 | |
| Glaxosmithkline, LLC. | $59.19 | 2022-2023 | Ojjaara |
| Seagen INC. | $49.14 | 2022-2023 | Padcev |
| Gilead Sciences, INC. | $49.04 | 2021-2023 | |
| Celgene Corporation | $44.44 | 2024 | Pomalyst |
| Regeneron Healthcare Solutions, INC. | $36.89 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $30.20 | 2021-2023 | Jakafi |
| Janssen Biotech, INC. | $29.31 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $28.94 | 2020-2022 | |
| Pharming Healthcare, INC. | $25.44 | 2019 | |
| Apellis Pharmaceuticals, INC. | $25.32 | 2024 | Empaveli |
| Sun Pharmaceutical Industries INC. | $24.97 | 2022 | |
| Adc Therapeutics America, INC. | $24.60 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.13 | 2021 | |
| Genentech USA, INC. | $15.50 | 2023 | Phesgo, Tecentriq |
| Ipsen Biopharmaceuticals, INC | $15.50 | 2024 | Onivyde |
| Kite Pharma, INC. | $15.39 | 2024 | Yescarta |
| Abbvie INC. | $15.09 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $14.60 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.43 | 2021 | |
| Dova Pharmaceuticals | $13.64 | 2021 | |
| Recordati_rare_diseases_inc. | $13.56 | 2023 | Sylvant |
| Tg Therapeutics, INC. | $11.36 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.